Literature DB >> 16365774

[Systemic therapy of chronic venous diseases].

S Reich1, P Altmeyer, M Stücker.   

Abstract

The therapy of chronic venous insufficiency is multifactorial. Compression, interventional and operative approaches are available along with the possibility of systemic treatment. The efficacy of systemic venotonic medications, mostly phytotherapeutic agents, is controversial. Nonetheless in a number of clinical and laboratory studies, an effect was seen after use for 8-12 weeks. When administered appropriately, venotonic agents can show anti-edematous, anti-inflammatory, anti-oxidative, proteolytic effects as well as reducing capillary leakage. Furthermore they increase vein tone and lymph flow. Venotonic agents should be used if compression therapy alone is either not sufficient, contraindicated or not tolerable. They can be useful as a temporizing measure until surgical intervention is performed. Some of them can even be used in pregnancy, but the indications are very strict.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16365774     DOI: 10.1007/s00105-005-1065-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  23 in total

1.  Possible mechanisms for the venular constriction elicited by Ruscus extract on hamster cheek pouch.

Authors:  E Bouskela; F Z Cyrino; G Marcelon
Journal:  J Cardiovasc Pharmacol       Date:  1994-07       Impact factor: 3.105

Review 2.  Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon.

Authors:  R W Frick
Journal:  Angiology       Date:  2000-03       Impact factor: 3.619

3.  Chemical structure of flavonols in relation to modulation of angiogenesis and immune-endothelial cell adhesion.

Authors:  Jong-Deog Kim; Liping Liu; Weimin Guo; Mohsen Meydani
Journal:  J Nutr Biochem       Date:  2005-08-02       Impact factor: 6.048

4.  Effects of flavonoids on rat aortic smooth muscle contractility: structure-activity relationships.

Authors:  M D Herrera; A Zarzuelo; J Jiménez; E Marhuenda; J Duarte
Journal:  Gen Pharmacol       Date:  1996-03

5.  Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195: a randomised, double-blind, placebo-controlled, crossover study.

Authors:  Ulrich Kalus; Juergen Koscielny; Alexandre Grigorov; Eckhard Schaefer; Hubertus Peil; Holger Kiesewetter
Journal:  Drugs R D       Date:  2004

6.  Mediators involved in inflammation: effects of Daflon 500 mg on their release.

Authors:  T Jean; M C Bodinier
Journal:  Angiology       Date:  1994-06       Impact factor: 3.619

7.  Cutaneous microcirculation in skin lesions associated with chronic venous insufficiency.

Authors:  M Stücker; M C Schöbe; K Hoffmann; U Schultz-Ehrenburg
Journal:  Dermatol Surg       Date:  1995-10       Impact factor: 3.398

8.  Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomised, double-blind, placebo-controlled clinical trial.

Authors:  N Ihme; H Kiesewetter; F Jung; K H Hoffmann; A Birk; A Müller; K I Grützner
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

9.  Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial.

Authors:  H Kiesewetter; J Koscielny; U Kalus; J M Vix; H Peil; O Petrini; B S van Toor; C de Mey
Journal:  Arzneimittelforschung       Date:  2000-02

10.  Anti-elastase and anti-hyaluronidase activities of saponins and sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: factors contributing to their efficacy in the treatment of venous insufficiency.

Authors:  R M Facino; M Carini; R Stefani; G Aldini; L Saibene
Journal:  Arch Pharm (Weinheim)       Date:  1995-10       Impact factor: 3.751

View more
  1 in total

1.  [Chronic venous insufficiency: Update on pathophysiology, diagnosis and treatment].

Authors:  P Gkogkolou; V Meyer; T Goerge
Journal:  Hautarzt       Date:  2015-05       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.